Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on February 27, 2019. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance metrics.
Material Changes
- Board Appointment: On February 27, 2019, the Company appointed Lara Sullivan, M.D. to the Board of Directors, effective immediately.
- Committee Assignments: Dr. Sullivan was appointed Chair of the newly formed Business Development Committee and as a member of the Nominating and Corporate Governance Committee.
- Compensation: Dr. Sullivan received an award of stock options to purchase 84,968 shares of common stock under the 2013 Stock Option Plan. She will also receive a pro-rated portion of the 2019 annual retainer and committee fees.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. It references a press release issued on March 1, 2019, regarding the appointment (Exhibit 99.1). Dr. Sullivan's background includes roles as President of SpringWorks Therapeutics, Vice President at Pfizer, and consultant at McKinsey & Company.
Investor Verification Checklist
- Verify the exact number of shares underlying the stock option grant (84,968) and the exercise price, which are not detailed in this summary text.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the terms of the pro-rated director compensation for the 2019 fiscal year.
- Note the discrepancy between the requested company name (Opus Genetics) and the actual registrant (Rexahn Pharmaceuticals).